Hints and tips:
Related Special Reports
...A team whose members include D2 Legal Technology, Standard Chartered bank, law firm Juris Corp, blockchain company SETL and 3 Hare Court Chambers is working on creating a marketplace for banks to buy legal...
...The price/earnings ratio of Edwards Lifesciences and Terumo are a third higher. Even a small refocusing of Olympus’s image could lead to handsome gains....
...Many Indian entrepreneurs have been slowing organic expansion at home and boosting foreign buyouts, such as UPL Corp’s takeover of US-based Arysta LifeScience....
...Medical technology group Integra LifeSciences has announced plans to buy Johnson & Johnson’s Codman neurosurgery business for just over $1bn in cash....
...Edwards Lifesciences reported earnings per share of 94 cents, above estimates of 82 cents and beating its results from the first quarter of 2016....
...Backed by Bill Ackman’s Pershing Square hedge fund, Platform Speciality has in the past year added to its portfolio Arysta LifeSciences for $5.4bn, and OM Group for $365m....
...Edwards Lifesciences Corp rose 1.87 per cent to close at $145.12. Genworth Financial and Western Digital Corp shed last week’s gains, falling 3.36 per cent to $7.48 and 1.30 per cent to $79.82....
...The acquisitive model for Platform Specialty is a replication of Mr Franklin’s consumer products business Jarden Corp....
...device maker received an unfavourable ruling from a federal court in Delaware banning it from selling its aortic heart valve replacement system, which was earlier found to infringe a patent by rival Edwards Lifesciences...
...Stuart’s early career began at Oracle and he has worked on major data and information initiatives for companies including United Healthcare Group, Edwards Lifesciences and most recently Spectrum Pharmaceuticals...
...Edwards Lifesciences tumbled 21.2 per cent to $84.6, making it the worst-hit stock on the S&P 500, after the cardiovascular equipment maker warned that third-quarter revenues would be lower than expected...
...Edwards Lifesciences tumbled 14 per cent to $92.30 in after-market trading as the maker of cardiovascular equipment said sales for the third quarter would fall short of market expectations....
...Gold explorer and miner Integra Mining jumped 27 per cent to A$0.40 after rival Silver Lake Resources said it was purchasing the company for A$0.45 a share, valuing the group at A$426m....
...Edwards Lifesciences climbed 5.1 per cent to $67.85, on the back of upgrades from several analysts. A Morgan Keegan noted pointed to the group’s strong product pipeline and prospects in China....
...Siemens has 4 per cent, but the most interesting investor is Edwards Lifesciences, world market leader in heart valves, which is quoted on the New York Stock Exchange with a market capitalisation of $8bn...
...Edwards LifeSciences tumbled after the administrator of the government’s Medicare and Medicaid programmes dealt a blow to hopes of a rapid roll-out for its new cardiovascular device....
...Deutsche Bank, for example, said on Tuesday that it expects to post a net gain of €500m ($705m) in 2011 from its “Project Integra” strategy of more closely integrating its corporate and investment banking...
...consequence of money that was imprudently lent and was then foolishly spent, especially by people in underprivileged areas that are now the ones paying the price,” says Michael Cannon, executive director of Integra...
...Edwards Lifesciences dropped 4.9 per cent to $52.15 as Goldman Sachs cut its recommendation on the company, which is focused on developing treatments for cardiovascular diseases, from “buy” to “neutral”...
...The deal for Bellsystem24 will rank as Japan’s largest buy-out by a foreign private equity firm since March 2008, when Permira bought Arysta LifeScience Corporation, an agrichemical company, for more than...
...For Permira, it would be its second major investment in Japan, following its Y250bn acquisition of Arysta LifeScience, the agrichemicals group, last year....
...Aurobindo will provide it with the rights to market 60 generic drugs in 70 countries, and Claris Lifesciences with a further 15 injectable medicines....
...Both companies compete with Edwards Lifesciences in the fast-growing market, which could eventually replace open-heart surgery for the 300,000 patients who need an aortic valve replacement every year....
...Navid Malik, analyst at Matrix Corp, said the deal was likely to signal a wave of further deals. “This gives Glaxo instant gratification,” he said....
...A unit of private equity firm Permira is buying Arysta LifeScience, a Japanese agribusiness based in Tokyo for $2.2bn from Olympus Capital Holdings Asia in the largest buy-out in Japan this year....
International Edition